BCRP

乳腺癌耐药蛋白(BCRP/ABCG2/MXR/ABCP)是一种 ATP 依赖性外排转运蛋白,属于存在于细胞膜上的大型 ATP 结合盒 (ABC) 转运蛋白家族,并被归类为这些转运蛋白的 G 亚家族。BCRP 在多种正常细胞中表达,并充当外来化合物外排转运蛋白。BCRP 通常与癌症化疗耐药性有关。BCRP 使一系列抗肿瘤药物(如米托蒽醌、柔红霉素、SN-38 和拓扑替康)产生多药耐药性 (MDR),并且通常会限制化疗的疗效。

BCRP 在生理上是生物体自我防御机制的一部分。它增强肠道和胆道中有毒外来化合物和有害物质的消除,以及通过血脑屏障、胎盘屏障和可能的血睾屏障。BCRP 识别和运输多种抗癌药物,包括传统化疗药物和临床应用相对较新的靶向小分子治疗药物。因此,癌细胞中的 BCRP 表达通过抗癌药物的主动流出直接导致 MDR。由于 BCRP 也被认为是一种干细胞标记物,其在癌细胞中的表达可能是代谢和信号通路的一种表现,这些通路赋予多种药物耐药性、自我更新(干细胞性)和侵袭性(侵袭性)机制,从而导致预后不良。因此,阻断 BCRP 介导的主动流出可能为癌症提供治疗益处。

Breast cancer resistance protein (BCRP/ABCG2/MXR/ABCP) is an ATP-dependent efflux transporter, which belongs to the large ATP-binding cassette (ABC) transporter family present on cell membranes, and it is classified into the G subfamily of these transporters. BCRP is expressed in a variety of normal cells and acts as a xenobiotic efflux transporter. BCRP is often associated with cancer chemotherapeutic resistance. BCRP confers multidrug resistance (MDR) to a series of antitumor agents such as Mitoxantrone, Daunorubicin, SN-38, and Topotecan, and often limits the efficacy of chemotherapy.

BCRP physiologically functions as a part of a self-defense mechanism for the organism. It enhances elimination of toxic xenobiotic substances and harmful agents in the gut and biliary tract, as well as through the blood-brain, placental, and possibly blood-testis barriers. BCRP recognizes and transports numerous anticancer drugs including conventional chemotherapeutic and targeted small therapeutic molecules relatively new in clinical use. Thus, BCRP expression in cancer cells directly causes MDR by active efflux of anticancer drugs. Because BCRP is also known to be a stem cell marker, its expression in cancer cells could be a manifestation of metabolic and signaling pathways that confer multiple mechanisms of drug resistance, self-renewal (stemness), and invasiveness (aggressiveness), and thereby impart a poor prognosis. Therefore, blocking BCRP-mediated active efflux may provide a therapeutic benefit for cancers.

共 1种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
Xanthine oxidase-IN-23

Xanthine oxidase-IN-23 (Compound BPF) 是一种具有口服活性的可逆混合型 Xanthine oxidase 抑制剂,其 IC50 为 3.33 μM,可通过以可逆混合型方式直接结合 XOD 抑制其催化活性,并上调 ABCG2、下调 GLUT9 以促进肾脏尿酸排泄,从而降低高尿酸血症小鼠的血清尿酸水平并改善其肾功能,因此可用于高尿酸血症的研究。

3055112-52-9
Activator
Xanthine oxidase-IN-23

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础